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Abstract
Background: Familial Mediterranean Fever is an autoinflammatory disease typically expressed with recurrent attacks
of fever, serositis, aphthous stomatitis, rash. Only a few reports describe the association with hepatic involvement.
Case presentation: We describe the clinical case of a child affected, since the age of 1 year, by recurrent fever,
aphthous stomatitis, rash, arthralgia, associated with abdominal pain, vomiting, lymphadenopathy. The diagnosis of
Familial Mediterranean Fever was confirmed by the genetic study of MEFV gene; the homozygous mutation M694 V
in exon was documented. A partial control of attacks was obtained with colchicine. The child continued to manifest
only recurrent episodes of abdominal pain without fever, however serum amyloid A persisted high, in association
with enhanced levels of CRP, AST and ALT (1.5 x n.v.). The dosage of colchicine was increased step by step and the
patient achieved a better control of symptoms and biochemical parameters. However, the patient frequently
needed an increase in the dose of colchicine, suggesting the possible usefulness of anti-interleukin-1 beta
treatment.
Conclusions: The unusual presentation of Familial Mediterranean Fever with liver disease suggests the role of
inflammasome in hepatic inflammation. Colchicine controls systemic inflammation in most of the patients;
however, subclinical inflammation can persist in some of them and can manifest with increased levels of CRP, ESR,
serum amyloid A also in attack-free intervals.
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Background
Familial Mediterranean Fever (FMF) is an autoinflam-
matory disease typically expressed with recurrent at-
tacks of fever, serositis leading to abdominal, thoracic
or articular pain, aphthous stomatitis, erysipelas-like
erythema [1]. Only a few reports in the international
literature describe the association with hepatic in-
volvement, documented by ultrasound and increased
levels of AST, ALT, gamma-GT, C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR). In these
cases, an accurate differential diagnosis is needed to
exclude other immune-mediated or infectious diseases
mimicking a liver disease [2, 3].
Case presentation
We report on a 10.6-year-old child affected, since the
age of 1 year, by recurrent fever, aphthous stomatitis,
rash, arthralgia, associated with abdominal pain, vomit-
ing, lymphadenopathy. Recurrence was every 15–30
days. Serum amyloid A (SAA) levels were 33mg/l, CRP
was 24.8 mg/dl, ESR was 86, AST and ALT were 1.5 x
n.v.. Though, he showed a height gain corresponding to
age (stature: 132.2 cm: - 1.55 SDS; weight: 27 kg: - 1.72
SDS), he did not showed obesity with a Body Mass Index
of 15.5 (− 1.3 SDS).
The diagnosis of FMF was considered for the clinical
presentation of the child [1] and confirmed at the age of 6
years by the genetic study of MEFV gene. The patient
showed a homozygous mutation of exon 10: M694 V.
Therefore, he started the treatment with colchicine at the
dosage of 0.03mg/kg/day. The grandfather died for renal
insufficiency. The parents did not refer recurrent fever
and/or other symptoms associated with FMF, and they did
not agree to be investigated genetically for FMF.
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A partial control of attacks was gained by colchicine
(however, recurrent episodes of abdominal pain,
without fever persisted) and increased levels of SAA
persisted. For these reasons, the dosage of colchicine
was gradually increased to 0.05 mg/kg/day, following
the regular weight gain during growth, with a good
control of biochemical parameters. SAA showed high
levels (33–223.8 mg/l: n.v.: < 6.4) in some phases of
the follow up, in correlation with the dosage of colchi-
cine. However, the normalization was achieved after
the progressive increase of the dose.
Abdominal ultrasound documented lymphadenopathy
and an echography pattern of “starry sky liver” (Fig. 1)
consensual with the phases of the disease characterized
by a significant increase of SAA and a mild increase of
AST, ALT (1.5 x n.v.). A better control of the disease
with increased doses of colchicine, however, allowed to
normalize SAA, AST, ALT levels and liver ultrasound
pattern. These data confirm that liver involvement was
not secondary to colchicine toxicity. Furthermore, the
patient maintained a low BMI, excluding obesity as a
cause of hepatopathy. He did not assume other drugs
further than colchicine that could contribute to the
increase of transaminases or induce hepatopathy.
Currently, SAA is 1.77 mg/l; CRP: 0.18; AST: 24;
ALT: 28; urinalysis is in the normal range without
microalbuminuria (Table 1).
Discussion and conclusions
We described this case for the unusual presentation
of FMF with fever, rash, aphthous stomatitis, liver
disease, not associated to other conditions, as infec-
tions, drugs intolerance [2], autoimmune disease, ce-
liac disease [4]. The described case underscores the
chance that MEFV mutations provide hepatic inflam-
mation, as seen in this child, by the inflammasome
involvement.
The reported case of a male child with FMF, present-
ing recurrent episodes of hepatitis (spontaneously re-
solved) during fever attacks or disease phases with a
low control by colchicine, highlight the role of an ap-
propriate colchicine dosage in the control of inflamma-
tion. In this view, the inflammatory role of the disease
in the liver involvement is confirmed by the consensual
increase of SAA, AST, ALT. Therapeutic trial with in-
creased doses of colchicine was successful, confuting
the hypothesis of the possible role of colchicine toxicity
in this case.
Cryptogenic liver disease was described in patients
with FMF only in a few studies [5, 6]. However, the
cases reported in the international literature showed
more frequently the M694 V mutation, especially in
homozygous state.
Some studies reported the safety profile of IL-1
blockers from real life [7]. We discussed with the parents
and the patient the opportunity to shift treatment to
canakinumab, a fully human anti- interleukin (IL)-1 beta
monoclonal antibody, to better control the inflammatory
state of the patient and the symptoms.
Canakinumab has not been started yet, because at the
last visit SAA levels were in the normal range and the
patient was asymptomatic. However, the opportunity to
shift the treatment to canakinumab for this patient could
be the optimal choice to minimize the inflammatory
state and to control the risk of amyloidosis, improving
long-term prognosis and quality of life.
Fig. 1 Abdomen ultrasound of the patient, showing a "starry-sky liver"
Table 1 Outcome of biochemical parameters of the patient
Colchicine mg/day (mg/kg/day) SAA (mg/l) CRP (mg/dl) ESR AST ALT GGT microalbuminuria (n.v.: 0–20mg/l)
at the admittance 33 24.8 86 82 68 21 9198
At 6.9 years 0.75 (0.03) 32.4 0.23 17 26 32 20 9400
At 8.2 years 1.25 (0.05) 223.8 7 42 76 62 33 4
At 10.6 years 1.5 (0.05) 1.77 0.18 11 24 28 12 10.5
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